טוען...
ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
Novel action beta‐blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5‐HT1α receptors to demonstrate pro‐anabolic, anti‐catabolic, and appetite‐stimulating actions. In the ACT‐ONE trial, espindolol reversed weight loss and improved handgrip...
שמור ב:
| הוצא לאור ב: | J Cachexia Sarcopenia Muscle |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5011815/ https://ncbi.nlm.nih.gov/pubmed/27625919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcsm.12136 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|